A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

12.1K views

⸱

DOI:

10.3791/58291

⸱

January 19th, 2019

 ,  ,  ,  ,  , 

* These authors contributed equally

In This Article

Summary

This protocol describes how to assess synergism between an anticancer antibody and antineoplastic drugs in preclinical models by using the combination index equation of Chou and Talalay.

Abstract

Potentiation of hostile monoclonal antibodies (mAb) by chemotherapeutic agents constitutes a valuable strategy for designing effective and safer therapy against cancer. Here we provide a protocol to identify a rational combination at the preclinical step. First, we describe a cell-based assay to assess the synergism between anticancer mAb and cytotoxic drugs, that uses the combination index equation of Chou and Talalay1. This includes the measurement of tumor cell drug- and antibody-sensitivity using an MTT assay, followed by an automated computer analysis to calculate the combination index (CI) values. CI values of <1 indicate synergism between tested mAbs and cytotoxic agents1. To corroborate the in vitro findings in vivo, we further describe a method to assess the combination regimen efficacy in a xenograft tumor model. In this model, the combined regimen significantly delays tumor growth, which results in a significant extended survival in comparison to single-agent controls. Importantly, the in vivo experimentation reveals that the combination regimen is well tolerated. This protocol allows the effective evaluation of anticancer drug combinations in preclinical models and the identification of rational combination to evaluate in clinical trials.

Introduction

The conventional approach in the treatment of a large number of different types of cancer was based on monotherapy. Even if it is still used in many cases, this method met several obstacles leading to opting for combined therapies2. Particularly, cancer cells are more susceptible to develop resistance when treated with a single drug by inducing alternative survival mechanisms3, resulting in therapeutic failure in patients4. Moreover, in monotherapy, drugs are usually administrated at a high dose. This situation often results in the occurrence of strong dose-dependent side effects that can be intol....

Access restricted. Please log in or start a trial to view this content.

Protocol

Animal housing and experimental procedure were approved by the French Government (agreements #C44-278 and #APAFIS 03479.01). Animal care and procedures were conducted under directive EU 2010/63/EU and French Law #2013-118 on the protection of animals used for scientific purposes.

1. Evaluation of the Drug Interaction Between mAb 8B6 and Topotecan In Vitro

  1. 96-well sample preparation
    CAUTION: Consult the institution's Health and Safety committee and follow local regulation rules related to laboratory safety. Review the Material and Safety Data Sheet information before working with any media, ce....

Access restricted. Please log in or start a trial to view this content.

Results

The representative results and figures are adapted with permission from earlier published work14.

Anti-OAcGD2 mAb 8B6 Synergistically Enhances the Inhibitory Effects of Topotecan on Neuroblastoma Cell Line Growth:

To establish the drug and the antibody concentrations to be used for assessing synergism between topotecan and mAb 8.......

Access restricted. Please log in or start a trial to view this content.

Discussion

To predict the effect of drug interactions, three methods can be used: the isobologram methodology17, the nonlinear mixture model18, and the combination index1. Combination index analysis is the most commonly used because its application is simplified by the availability of a user-friendly computer program. For this purpose, we first characterized the dose-effect response of each agent used alone or in combination, by performing an MTT assay

Access restricted. Please log in or start a trial to view this content.

Disclosures

S.Fa., J.F., and S.B. are designated as inventors of pending patents covering the clinical application of anti-O-acetyl-GD2 therapeutic antibodies.

Acknowledgements

Grant support: Fondation de Projet de L'Université de Nantes, les Bagouz' à Manon, La Ligue contre le Cancer comité de Loire-Atlantique, comité du Morbihan, and comité de Vendée, une rose pour S.A.R.A.H, L'Etoile de Martin and la Société Française de Lutte contre les Cancers et les leucémies de L'Enfant et de L'adolescent (SFCE). M.B. and J.F. are supported by La Ligue Contre Le Cancer. The authors thank the UTE-facility of the Structure Fédérative de Recherche François Bonamy. The authors also thank Dr. S. Suzin (Inserm, Paris) for providing the IMR5 cells and Ms. H. Estéph....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
Cell Proliferation kit (MTT)Roche11-465-007-001
CompuSyn softwareComboSynCombosyn can be downloaded for free at http://www.combosyn.com
Electric shaverBiosebBIO-1556
Fetal calf serumEurobioCVFSVFF00-0110% heat-inactivated fetal calf serum in RPMI 1640
Firefox Mozilla CorporationFirefox can be downloaded for free at http://www.mozilla.org/en-US/firefox/
Heat lampVerre&Quartz4003/1R
Human neuroblastoma IMR-5 cell lineAccegen BiotechnologyABC-TC0450IMR-5 is a clone of the human neuroblastoma cell line IMR32 5459762. IMR-5 cells were generously provided by Dr. Santos Susin (U.872, Paris, France)
L-glutamineGibco25030-0242 mM in RPMI 1640
Lysis solution Roche 11-465-007-001
mAb 8B6University of NantesN/A
MatrigelCorning354248
Multiskan FCThermofischer Scientific N08625
Needle 21G 1 ½ BD Microlance304432
Needle 25G 1TerumoNN-2525R
NSG miceCharles River Laboratories5557
Nunc MicroWell 96-well microplatesThermofisher167008
PBSVWRL182-10
PBS, 0,05% EDTASigma-AldrichE9884
PC that runs windows 7MicrosoftWindows 7 can be purchased at http://www.microsoft.com/en-gb/software-download/windows7
Penicillin-StreptomycinGibco15140-122100 units/mL penicillin and 100 mg/mL streptomycin in RPMI 1640
Reagent reservoirThermofischer Scientific8094
Rodent restrainerBiosebTV-150-SM
RPMI 1640Gibco31870-025
Syringe 1 mLHenke Sass Wolf5010.200V0
TopotecanSigma-AldrichT2705

References

  1. Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological Reviews. 58 (3), 621-681 (2006).
  2. Bayat Mokhtari, R., et al. Combination therapy ....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Chemotherapeutic DrugsMTT AssayXenograft Tumor ModelCell Viability AssaySerial DilutionsSynergism DetectionTumor Growth InhibitionDrug Combination Therapy